Trial Profile

A Phase I/II Clinical Trial Testing the Safety and Feasibility of IL-21- Expanded Natural Killer Cells for the Induction of Relapsed/Refractory Acute Myeloid Leukemia

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 03 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cytarabine (Primary) ; Filgrastim (Primary) ; Fludarabine (Primary) ; Granulocyte colony-stimulating factors (Primary) ; K NK003 (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions

Most Recent Events

29 Aug 2020 According to a Kiadis Pharma media release, this study is sponsored by the Brazilian Agencies for Research development.
29 Aug 2020 Results (n=13) presented in a Kiadis Pharma media release.
29 Aug 2020 According to a Kiadis Pharma media release, data from this trial is being presented in an e-poster at the Virtual Edition of the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com